rmc-6236
Small moleculeexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
6
Phase 3
3
Phase 4
0
Earliest trial started May 31, 2022 (NCT05379985)
Timeline
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07252232 | Phase 3 | Dec 10, 2025 | Revolution Medicines, Inc. |
| NCT06922591 | Phase 1/Phase 2 (Phase 2) | May 31, 2025 | Revolution Medicines, Inc., Tango Therapeutics, Inc. |
| NCT06881784 | Phase 3 | May 6, 2025 | Revolution Medicines, Inc. |
| NCT06625320 | Phase 3 | Oct 16, 2024 | Revolution Medicines, Inc. |
| NCT06445062 | Phase 1/Phase 2 (Phase 2) | May 24, 2024 | Revolution Medicines, Inc. |
| NCT06162221 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2023 | Revolution Medicines, Inc. |
| NCT05379985 | Phase 1 | May 31, 2022 | Revolution Medicines, Inc. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Revolution Medicines, Inc. | For profit | 7 | 6 | 3 | 2022 |
| Tango Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1